Mochi Health vs Ivim Health: Coverage vs Cash-Pay Compounding

This article is part of the PlexusDx Education Hub, a library of evidence-based guidance on GLP-1 therapies, weight-management protocols, and the genetic factors that shape metabolic care. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx has no commercial relationship with Mochi Health or Ivim Health and includes no affiliate links or compensation.

Mochi Health and Ivim Health sit on opposite sides of one question: how you pay. Mochi Health leans on insurance-support, while Ivim Health centers a compounded-pharmacy pathway that is typically cash-pay. This overview compares the two programs through the lens of coverage and cost structure, then turns to the genetic dimension that lives outside both. As of April 2026, the category is crowded; this focuses on the two brands named.

Mochi Health’s insurance-support approach

Mochi Health frames its telehealth around helping members work with existing insurance coverage, so the experience can involve plan navigation and benefit checks rather than a single flat charge. Because coverage varies by plan and product, the Mochi Health website is the reliable source for what applies to you today.

Ivim Health’s compounded-pharmacy approach

Ivim Health combines telehealth with a compounded-pharmacy pathway, routing prescriptions to a retail pharmacy for branded products or a 503A compounding pharmacy for compounded semaglutide or tirzepatide. This model is generally cash-pay, with pricing tied to the product and tier. Confirm the current structure on the Ivim Health website.

Coverage, cash-pay, and what each really means

An insurance-support model can lower your out-of-pocket cost when your plan covers part of the therapy, but it adds variables like prior authorization and formulary rules. A cash-pay compounding model offers predictability and often access to compounded options, but without insurance offset. The better fit depends on your coverage and your appetite for administrative steps.

The evidence belongs to the compound

How you pay does not change what you take. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual GIP/GLP-1 agonist tirzepatide carry the trial record, from STEP (NEJM 2021) to SURMOUNT (NEJM 2022) and SURMOUNT-OSA (NEJM 2024). Whether the cost runs through insurance or cash, the pharmacology is the same.

Reading a real quote before you commit

A headline figure rarely equals what you pay. On an insurance-support path, ask what the estimate assumes about your plan, whether prior authorization is required, and what happens if coverage is denied. On a cash-pay compounding path, ask what the quoted price includes, whether the medication is branded or compounded, and how the number changes as your dose escalates. Comparing two fully loaded quotes, rather than two advertised starting prices, is the only way to know which model is genuinely cheaper for you.

The genetic dimension outside both programs

Coverage models say nothing about your biology. A variant in TCF7L2, tied to glucose homeostasis and GLP-1 secretion, along with FTO and MC4R, describes the metabolic baseline any GLP-1 protocol enters. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights across that dimension, and it never predicts your response to a specific compound.

Where PlexusDx sits in this picture

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, sold as Semaglutide Injection ($189/month), Semaglutide Oral, Tirzepatide Injection ($289/month), and Tirzepatide Oral. Beginning with the Precision Peptide Genetic Test adds the genetic dimension that coverage-focused comparisons overlook.

Not affiliated: PlexusDx has no commercial relationship with Mochi Health, Ivim Health, or any brand referenced here.

Keep reading on PlexusDx: GLP-1 Receptor Agonist, GLP-1 Drugs, GLP-1 Hormone, What Is GLP-1.

Editorial note: this comparison is educational only. PlexusDx sells semaglutide and tirzepatide through its own Weight Management Protocols and is not affiliated with the reviewed brands. The Precision Peptide Genetic Test reports genetic influence on peptide pathways and does not predict medication response. Speak with a qualified provider before starting a protocol.

Frequently Asked Questions

Does Mochi Health accept insurance and Ivim Health not?

Mochi Health builds insurance-support into its model, while Ivim Health compounded-pharmacy pathway is generally cash-pay. Whether insurance actually covers your therapy still depends on your specific plan, the medication, and authorization rules, so verify current terms directly with each program.

Is a cash-pay compounding program more predictable?

It can be, because cash pricing is set rather than filtered through plan design. The tradeoff is the absence of an insurance offset. An insurance-support model may cost less when your plan pays part of the therapy, so the more predictable choice depends on your coverage situation.

Do both programs offer the same GLP-1 medications?

Both work within the GLP-1 class and may provide semaglutide or tirzepatide subject to eligibility and supply, though the dispensing route differs, with Ivim Health emphasizing a compounded pathway. Confirm each current catalog, since branded and compounded availability changes over time.

How does genetic testing relate to coverage decisions?

Genetic testing is independent of how you pay. The Precision Peptide Genetic Test maps variants such as TCF7L2 and FTO that describe your metabolic baseline, offering context that stays relevant whether your therapy runs through insurance-support or a cash-pay compounding program.

This article belongs to the PlexusDx Education Hub. Browse all Peptides & GLP-1 education